Literature DB >> 30675730

Alternate quinone coupling in a new class of succinate dehydrogenase may potentiate mycobacterial respiratory control.

Kiel Hards1,2, Salome Molano Rodriguez1, Charlotte Cairns1, Gregory M Cook1,2.   

Abstract

There is a paucity of information on the unique components that pathogens use to form respiratory chains. It is not known why mycobacteria encode multiple succinate dehydrogenases (SDHs) to perform menaquinone-linked succinate oxidation, a thermodynamically unfavorable reaction (ΔG° = +21 kJ·mol-1 ). In other bacteria, specific di-heme SDHs overcome this using the proton motive force. It is unknown if this holds true in mycobacteria. Here, succinate dehydrogenase 1 (Sdh1) from Mycobacterium smegmatis was purified and found to not contain heme cofactors. Proteoliposomes, containing Sdh1, are active with coenzyme Q2 (Km  ~ 12 μm), are competitively inhibited by menaquinone (Ki  ~ 25 μm) and do not generate or consume electrochemical gradients. Sdh1 may use higher potential quinones in vivo and forms a novel SDH class, which we term 'Type F'.
© 2019 Federation of European Biochemical Societies.

Entities:  

Keywords:  bioenergetics; metabolism; mycobacteria; quinone; succinate dehydrogenase; tuberculosis

Year:  2019        PMID: 30675730     DOI: 10.1002/1873-3468.13330

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Crystallographic investigation of the ubiquinone binding site of respiratory Complex II and its inhibitors.

Authors:  Li-Shar Huang; Peter Lümmen; Edward A Berry
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2021-06-03       Impact factor: 4.125

2.  Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.

Authors:  Brendon M Lee; Liam K Harold; Deepak V Almeida; Livnat Afriat-Jurnou; Htin Lin Aung; Brian M Forde; Kiel Hards; Sacha J Pidot; F Hafna Ahmed; A Elaaf Mohamed; Matthew C Taylor; Nicholas P West; Timothy P Stinear; Chris Greening; Scott A Beatson; Eric L Nuermberger; Gregory M Cook; Colin J Jackson
Journal:  PLoS Pathog       Date:  2020-02-07       Impact factor: 6.823

Review 3.  Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis.

Authors:  Matthew B McNeil; Chen-Yi Cheung; Natalie J E Waller; Cara Adolph; Cassandra L Chapman; Noon E J Seeto; William Jowsey; Zhengqiu Li; H M Adnan Hameed; Tianyu Zhang; Gregory M Cook
Journal:  Front Cell Infect Microbiol       Date:  2022-08-24       Impact factor: 6.073

4.  Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis.

Authors:  Cara Adolph; Matthew B McNeil; Gregory M Cook
Journal:  mBio       Date:  2022-07-20       Impact factor: 7.786

5.  A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks.

Authors:  Víctor A López-Agudelo; Tom A Mendum; Emma Laing; HuiHai Wu; Andres Baena; Luis F Barrera; Dany J V Beste; Rigoberto Rios-Estepa
Journal:  PLoS Comput Biol       Date:  2020-06-15       Impact factor: 4.475

6.  Cryo-EM structure of trimeric Mycobacterium smegmatis succinate dehydrogenase with a membrane-anchor SdhF.

Authors:  Hongri Gong; Yan Gao; Xiaoting Zhou; Yu Xiao; Weiwei Wang; Yanting Tang; Shan Zhou; Yuying Zhang; Wenxin Ji; Lu Yu; Changlin Tian; Sin Man Lam; Guanghou Shui; Luke W Guddat; Luet-Lok Wong; Quan Wang; Zihe Rao
Journal:  Nat Commun       Date:  2020-08-25       Impact factor: 14.919

7.  Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.

Authors:  Bei Shi Lee; Kiel Hards; Curtis A Engelhart; Erik J Hasenoehrl; Nitin P Kalia; Jared S Mackenzie; Ekaterina Sviriaeva; Shi Min Sherilyn Chong; Malathy Sony S Manimekalai; Vanessa H Koh; John Chan; Jiayong Xu; Sylvie Alonso; Marvin J Miller; Adrie J C Steyn; Gerhard Grüber; Dirk Schnappinger; Michael Berney; Gregory M Cook; Garrett C Moraski; Kevin Pethe
Journal:  EMBO Mol Med       Date:  2020-12-07       Impact factor: 14.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.